Stay updated on Nivolumab + HF10 for Resectable Melanoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page

  1. Check
    yesterday
    Change Detected
    Summary
    The ClinicalTrials.gov site revision in the footer changed from v3.8.0 to v3.8.1.
    Difference
    0.1%
    Check dated 2026-11-18T02:28:37.000Z thumbnail image
  2. Check
    8 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov record for the neoadjuvant nivolumab and HF10 melanoma trial is displayed with its study details, eligibility criteria, outcomes, and results. It identifies the trial as terminated and no longer recruiting participants.
    Difference
    46%
    Check dated 2026-11-11T01:38:34.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0 while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T23:51:02.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    A banner announces NIH website updates and a terminology transition from “Artificial Intelligence” to “Super Intelligence.” The site revision number changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-20T23:51:46.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The footer revision number advances from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-07T00:07:46.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error instead of the study details, replacing the content with a basic header/footer and preventing access to the study record.
    Difference
    18%
    Check dated 2026-09-22T23:52:19.000Z thumbnail image

Stay in the know with updates to Nivolumab + HF10 for Resectable Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page.